Axovant Sciences Ltd (NYSE:AXON)‘s stock had its “hold” rating reiterated by equities research analysts at Oppenheimer Holdings, Inc. in a report released on Sunday.
Several other brokerages have also weighed in on AXON. BidaskClub lowered Axovant Sciences from a “sell” rating to a “strong sell” rating in a research report on Friday, September 15th. HC Wainwright reissued a “buy” rating on shares of Axovant Sciences in a research report on Thursday, October 19th. Jefferies Group LLC set a $40.00 target price on Axovant Sciences and gave the stock a “buy” rating in a research report on Friday, August 25th. Evercore ISI reissued an “outperform” rating and set a $9.00 target price (down previously from $30.00) on shares of Axovant Sciences in a research report on Tuesday, September 26th. Finally, Piper Jaffray Companies lowered Axovant Sciences from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $32.00 to $9.00 in a research report on Tuesday, September 26th. Four equities research analysts have rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company’s stock. Axovant Sciences presently has an average rating of “Hold” and an average target price of $14.13.
Axovant Sciences (AXON) traded down $0.20 during mid-day trading on Friday, reaching $5.14. The company’s stock had a trading volume of 628,300 shares, compared to its average volume of 1,034,831. The company has a current ratio of 6.01, a quick ratio of 6.01 and a debt-to-equity ratio of 0.25. Axovant Sciences has a 52 week low of $4.60 and a 52 week high of $27.98.
Axovant Sciences (NYSE:AXON) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.12).
TRADEMARK VIOLATION NOTICE: “Axovant Sciences Ltd (AXON) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.chaffeybreeze.com/2017/11/13/axovant-sciences-ltd-axon-stock-rating-reaffirmed-by-oppenheimer-holdings-inc.html.
Several hedge funds have recently made changes to their positions in the business. FMR LLC grew its stake in shares of Axovant Sciences by 968.5% in the 2nd quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock valued at $167,794,000 after purchasing an additional 6,558,462 shares during the last quarter. Capital Research Global Investors grew its stake in shares of Axovant Sciences by 21.8% in the 2nd quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock valued at $80,094,000 after purchasing an additional 619,226 shares during the last quarter. Janus Henderson Group PLC purchased a new position in shares of Axovant Sciences in the 2nd quarter valued at approximately $47,854,000. OxFORD Asset Management LLP grew its stake in shares of Axovant Sciences by 842.1% in the 3rd quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock valued at $5,838,000 after purchasing an additional 777,505 shares during the last quarter. Finally, Eagle Asset Management Inc. purchased a new position in shares of Axovant Sciences in the 3rd quarter valued at approximately $4,471,000.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.